NEW YORK (GenomeWeb News) — Proteome Sciences' CEO Christopher Pearce has increased an existing loan facility to the company from £4 million ($8 million) to £6 million, the company said today.
 
Proteome said the additional cash will keep the company solvent until it starts recording revenue from its ProteoShop biomarker portfolio.
 
The expanded facility will also enable the firm to out-license its TMT products, which it expects to happen sometime during the next five months.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.